source
- Incyte claims double Phase 3 win in vitiligo, will file for approvalIncyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...Endpoints · 3mo ago↗ source
- STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededEli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news todaySTAT · 3mo ago↗ source
- STAT+: Google’s clinical director on AI challengesIn this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.STAT · 3mo ago↗ source